Ravi N. Munuganti

2660 Oak Street, V6H 3Z6
Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Cryo-EM-guided subtractive optimization of a novel VCP/p97 inhibitor.

Cryo-EM-guided subtractive optimization of a novel VCP/p97 inhibitor.

Journal: IUCrJ

Published: February 09, 2026

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.

Journal: Cancer research communications

Published: March 08, 2023

Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.

Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.

Journal: ACS chemical biology

Published: September 10, 2021

Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.

Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.

Journal: Cell reports

Published: August 17, 2021

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules.

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules.

Journal: Journal of the Endocrine Society

Published: June 03, 2018

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.

Journal: International journal of molecular sciences

Published: January 04, 2018

Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.

Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 27, 2017

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: June 02, 2016

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Journal: Molecular cancer therapeutics

Published: June 02, 2016

Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).

Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).

Journal: Journal of medicinal chemistry

Published: July 16, 2014

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Journal: Chemistry & biology

Published: May 29, 2014

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.

Journal: Breast cancer research : BCR

Published: February 12, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026